WATERTOWN, Mass., June 30, 2015 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Nathalie Adda, M.D., as Senior Vice President and Chief Medical Officer, responsible for clinical and regulatory affairs.
"Nathalie is a welcome addition to our executive management team. Her clinical and regulatory expertise will be invaluable to us as we prepare to advance our internal virology and liver disease programs," commented Jay R. Luly, Ph.D., President and CEO.
Dr. Adda is a specialist in infectious disease and has more than 15 years of experience in the pharmaceutical industry in all phases of global clinical research and development and commercialization. Most recently, Dr. Adda was Chief Medical Officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene SA, where she led the Oncology and Infectious Disease programs since 2012. From 2006 to 2012, she was Senior Medical Director and the medical lead for the Incivek® (telaprevir) Clinical Program at Vertex Pharmaceuticals Inc., where she designed the phase 2 and Phase 3 programs, and led the medical team in its successful marketing applications and registration in the USA, Canada, and, Asia. Earlier in her career, she held medical and research positions at Gilead, Triangle Pharmaceuticals and Boehringer Ingelheim, where she worked on programs for infectious diseases such as human immunodeficiency virus, hepatitis B virus and hepatitis C virus.
Dr. Adda is a graduate of the University of Paris, where she received a Doctorate in Medicine, as well as a Master's Degree in Biostatistics, and where she did post-graduate work in infectious diseases.
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A, and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Enanta's lead protease inhibitor, paritaprevir, is part of AbbVie's recently approved HCV treatment regimens. In addition, Enanta has a preclinical program in non-alcoholic steatohepatitis, or NASH, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver.